• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Curis Inc.

    11/6/25 4:27:20 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRIS alert in real time by email
    S-8 1 criss-8november2025.htm S-8 Document
    As filed with the Securities and Exchange Commission on November 6, 2025
    Registration No. 333-
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ________________________________

    FORM S-8
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
    ________________________________

    Curis, Inc.
    (Exact Name of Registrant as Specified in Its Charter)
    ________________________________

    Delaware
    04-3505116
    (State or Other Jurisdiction of Incorporation or Organization)
    (I.R.S. Employer Identification No.)
    128 Spring Street, Building C – Suite 500 Lexington, MA
    02421
    (Address of Principal Executive Offices)
    (Zip Code)

    Fifth Amended and Restated 2010 Stock Incentive Plan, as amended
    Inducement Stock Option Awards (May 1, 2025 - October 1, 2025)

    (Full Title of the Plan)
    James E. Dentzer
    President and Chief Executive Officer
    128 Spring Street, Building C – Suite 500
    Lexington, MA 02421
    (Name and Address of Agent For Service)

    (617) 503-6500
    (Telephone Number, Including Area Code, of Agent For Service)
    with a copy to:
    Cynthia T. Mazareas, Esq.
    Wilmer Cutler Pickering Hale and Dorr LLP
    60 State Street Boston, MA 02109
    (617) 526-6000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer ☐Smaller reporting company  ☒
    Non-accelerated filer☒Accelerated filer☐
    Emerging growth company☐



    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information.
    The information required by Item 1 with respect to the Fifth Amended and Restated 2010 Stock Incentive Plan, as amended (the “Plan”), of Curis, Inc. (the “Registrant”) is omitted from this registration statement and included in documents sent or given to participants in the Plan pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”) and the Note to Part I of Form S-8.
    The information required by Item 1 with respect to the inducement stock option awards granted during the period May 1, 2025 through October 1, 2025 (the “Inducement Awards”) is omitted from this registration statement and included in documents sent or given to the recipients of the Inducement Awards pursuant to Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8.
    Item 2. Registrant Information and Employee Plan Annual Information.
    The written statement required by Item 2 with respect to the Plan is omitted from this registration statement and included in documents sent or given to participants in the Plan pursuant to Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8.
    The written statement required by Item 2 with respect to the Inducement Awards is omitted from this registration statement and included in documents sent or given to the recipients of the Inducement Awards pursuant to Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.
    This registration statement is being filed to register the offer and sale of an additional 1,255,000 shares of Common Stock, $0.01 par value per share, of the Registrant (the “Common Stock”) to be issued under the Plan. In accordance with General Instruction E to Form S-8, except for Item 5 “Interests of Named Experts and Counsel” and Item 8 “Exhibits,” this registration statement incorporates by reference the contents of the registration statements on Form S-8 filed by the Registrant on June 22, 2010 (File No. 333-167675), September 10, 2013 (File No. 333-191074), August 12, 2015 (File No. 333-206323), December 14, 2018 (File No. 333-228811), December 13, 2019 (File No. 333-235499), December 4, 2020 (File No. 333-251144), October 15, 2021 (File No. 333-260278), and June 14, 2024 (File No. 333-280208) relating to the Plan.
    In addition, this registration statement is also being filed to register 84,750 shares of Common Stock issuable pursuant to the Inducement Awards.
    The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:
    (a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on March 31, 2025, including the information specifically incorporated by reference into the Annual Report on Form 10-K from the Registrant’s definitive proxy statement for the 2025 Annual Meeting of Stockholders.
    (b)The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, as filed with the Commission on May 6, 2025, Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, as filed with the Commission on August 5, 2025, and Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, as filed with the Commission on November 6, 2025.
    (c)The Registrant’s Current Reports on Form 8-K as filed with the Commission on February 27, 2025, March 28, 2025 (except with respect to Item 2.02 and Exhibit 99.1), May 22, 2025, July 2, 2025 (except with respect to Item 7.01 and Exhibit 99.1), August 8, 2025, August 22, 2025, October 24, 2025, and November 6, 2025 (except with respect to Item 2.02 and Exhibit 99.1).


    (d)The description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A as filed with the Commission on April 13, 2000, as the description therein has been updated and superseded by the description of the Registrant’s capital stock contained in Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on March 31, 2025, and including any amendments and reports filed for the purpose of updating such description.
    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.
    Item 4. Description of Securities.
    Not applicable.
    Item 5. Interests of Named Experts and Counsel.
    Not applicable.
    Item 6. Indemnification of Directors and Officers.
    Section 145 of the General Corporation Law of the State of Delaware (“DGCL”) provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.
    Section 102(b)(7) of the DGCL provides, generally, that a corporation’s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision may not eliminate or limit the liability of (i) a director or officer for any breach of the director’s or officer’s duty of loyalty to the corporation or its shareholders, (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) a director under section 174 of the DGCL, (iv) a director or officer for any transaction from which the director or officer derived an improper personal benefit, or (v) an officer in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such provision became effective.
    Article Sixth of the Registrant’s certificate of incorporation provides that no director shall be personally liable to the Registrant or any of its stockholders for any monetary damages for any breach of fiduciary duty as a director of the Registrant, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breach of fiduciary duty.
    Article Eighth of the Registrant’s certificate of incorporation provides, in general, that the Registrant shall indemnify each person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Registrant), by reason of the fact that such person is or was, or has agreed to become, a director


    or officer of the Registrant, or is or was serving or has agreed to serve, at the request of the Registrant, as a director, officer or trustee of, or in a similar capacity with, another corporation (including any partially or wholly owned subsidiary of the Registrant), partnership, joint venture, trust or other enterprise (including any employee benefit plan), against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any such action, suit or proceeding to the maximum extent permitted by the DGCL. The foregoing right of indemnification is in no way exclusive of any other rights of indemnification to which any such director or officer may be entitled, under any by-law, agreement, vote of directors or stockholders or otherwise.
    In addition to the indemnification provided by the Registrant’s certificate of incorporation and under the DGCL, the Registrant has entered into indemnification agreements with its executive officers and directors. The indemnification agreements provide that each such person:
    •shall be indemnified by the Registrant against all expenses (including attorneys’ fees), judgments, fines, penalties, and amounts paid in settlement incurred in connection with any litigation or other legal proceeding (other than an action by or in the right of the Registrant) brought against him or her by virtue of his or her position as an officer or director of the Registrant if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Registrant, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful; and
    •shall be indemnified by the Registrant against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement incurred in connection with any action by or in the right of the Registrant brought against him or her by virtue of his or her position as an officer or director of the Registrant if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Registrant, except that no indemnification shall be made with respect to any matter as to which such person shall have been adjudged to be liable to the Registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is fairly and reasonably entitled to indemnification of such expenses.
    Notwithstanding the foregoing, to the extent that an officer or director has been successful, on the merits or otherwise, he or she is required to be indemnified by the Registrant against all expenses (including attorneys’ fees) incurred in connection with defending any proceeding to the extent that the Registrant does not assume the defense of such proceeding. Expenses shall be advanced to an officer or director, provided that he or she undertakes to repay the amount advanced if it is ultimately determined that he or she is not entitled to indemnification for such expenses.
    Indemnification is required to be made unless the Registrant determines that the applicable standard of conduct required for indemnification has not been met. As a condition precedent to the right of indemnification, the officer or director must give the Registrant notice of the action for which indemnity is sought and the Registrant has the right to participate in such action or assume the defense thereof.
    The Registrant maintains a general liability insurance policy which covers certain liabilities of directors and officers of the Registrant arising out of claims based on acts or omissions in their capacities as directors or officers.
    Item 7. Exemption from Registration Claimed.
    Not applicable.



    Item 8. Exhibits.

    NumberDescription
    4.1
    Restated Certificate of Incorporation of Curis, Inc., as amended (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on May 22, 2025).
    4.2
    Certificate of Designations of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form S-3, filed on August 10, 2001 (File No. 333-50906)).
    4.3
    Amended and Restated By-laws of Curis, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed on May 22, 2025).
    5.1
    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the registrant.
    23.1
    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1.)
    23.2
    Consent of PricewaterhouseCoopers LLP, independent registered public accountant.
    24.1
    Power of attorney (included on the signature pages of this registration statement).
    99.1
    Fifth Amended and Restated 2010 Stock Incentive Plan, as amended (incorporated by reference to Appendix A to the Registrant’s Proxy Statement on Schedule 14A, filed on April 10, 2025)
    99.2
    Form of Nonstatutory Stock Option Agreement - Inducement Grant pursuant to Nasdaq Stock Market Rule 5635(c)(4) (incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8 filed on January 6, 2017 (File No. 333-215453)).
    107
    Filing Fee Table.
    Item 9. Undertakings.

    1.The undersigned registrant hereby undertakes:
    a.To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
    i.To include any prospectus required by Section 10(a)(3) of the Securities Act;
    ii.To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables”


    or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; and
    iii.To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
    provided, however, that paragraphs (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
    b.That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    c.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    2.The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    3.Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lexington, Commonwealth of Massachusetts, on November 6, 2025.

    CURIS, INC.
    By:/s/ Diantha Duvall
    Diantha Duvall
    Chief Financial Officer




    SIGNATURES AND POWER OF ATTORNEY

    We, the undersigned officers and directors of Curis, Inc., hereby severally constitute and appoint James E. Dentzer and Diantha Duvall and each of them singly, our true and lawful attorneys with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Curis, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ James E. DentzerPresident, Chief Executive Officer and Director
    (Principal Executive Officer)
    November 6, 2025
    James E. Dentzer
    /s/ Diantha DuvallChief Financial Officer
    (Principal Financial and Accounting Officer)
    November 6, 2025
    Diantha Duvall
    /s/ Martyn D. GreenacreChairman of the Board of DirectorsNovember 6, 2025
    Martyn D. Greenacre
    /s/ Anne BorgmanDirectorNovember 6, 2025
    Anne Borgman
    /s/ John A. HohnekerDirectorNovember 6, 2025
    John A. Hohneker
    /s/ Kenneth I. KaitinDirectorNovember 6, 2025
    Kenneth I. Kaitin
    /s/ Marc RubinDirectorNovember 6, 2025
    Marc Rubin

    Get the next $CRIS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRIS

    DatePrice TargetRatingAnalyst
    5/19/2025$17.00Buy
    H.C. Wainwright
    11/17/2023$26.00Buy
    Truist
    4/4/2022Outperform → Mkt Perform
    Raymond James
    10/13/2021$15.00Outperform
    Raymond James
    More analyst ratings

    $CRIS
    SEC Filings

    View All

    SEC Form S-8 filed by Curis Inc.

    S-8 - CURIS INC (0001108205) (Filer)

    11/6/25 4:27:20 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Curis Inc.

    10-Q - CURIS INC (0001108205) (Filer)

    11/6/25 4:09:06 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - CURIS INC (0001108205) (Filer)

    11/6/25 4:01:20 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Curis with a new price target

    H.C. Wainwright resumed coverage of Curis with a rating of Buy and set a new price target of $17.00

    5/19/25 8:52:11 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Curis with a new price target

    Truist initiated coverage of Curis with a rating of Buy and set a new price target of $26.00

    11/17/23 7:37:50 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis downgraded by Raymond James

    Raymond James downgraded Curis from Outperform to Mkt Perform

    4/4/22 11:27:43 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President & CEO Dentzer James E

    4 - CURIS INC (0001108205) (Issuer)

    5/22/25 4:13:54 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Hohneker John

    4 - CURIS INC (0001108205) (Issuer)

    5/22/25 4:13:41 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Greenacre Martyn D

    4 - CURIS INC (0001108205) (Issuer)

    5/22/25 4:13:30 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Curis Provides Third Quarter 2025 Business Update

    Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30, 2025. "We made good progress advancing our clinical studies in PCNSL, CLL, and AML this quarter. We continue to enroll PCNSL patients in the TakeAim Lymphoma study in both the BTKi-experienced and BTKi-naïve

    11/6/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

    LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

    10/30/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on October 1, 2025, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 84,750 shares of Curis common stock to two new employees, with a grant date of October 1, 2025 (the "Q4 2025 Inducement Grants"). Each of the Q4 2025 Inducement Grants has an exercise price per

    10/3/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Financials

    Live finance-specific insights

    View All

    Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

    LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

    10/30/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

    LEXINGTON, Mass., July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast c

    7/29/25 8:30:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

    LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

    4/29/25 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Leadership Updates

    Live Leadership Updates

    View All

    Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

    LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Devel

    1/3/22 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Appoints John A. Hohneker, M.D. To Board Of Directors

    LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industries.  He most recently served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company's transitio

    12/6/21 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants"). Each of the Q1 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on January 4, 2021. Each stock option has a 10 year term and vests ov

    1/8/21 4:01:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Curis Inc.

    SC 13G/A - CURIS INC (0001108205) (Subject)

    11/13/24 2:05:06 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Curis Inc.

    SC 13G - CURIS INC (0001108205) (Subject)

    11/1/24 4:35:37 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Curis Inc.

    SC 13G - CURIS INC (0001108205) (Subject)

    4/15/24 2:12:19 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care